enVVeno Medical
NVNO
22 hedge funds and large institutions have $13.7M invested in enVVeno Medical in 2022 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 6 increasing their positions, 2 reducing their positions, and 2 closing their positions.
5,263% more call options, than puts
Call options by funds: $3.38M | Put options by funds: $63K
200% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 2
69% more capital invested
Capital invested by funds: $8.11M → $13.7M (+$5.62M)
50% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 2
5% more funds holding
Funds holding: 21 → 22 (+1)
0.01% more ownership
Funds ownership: 0.65% → 0.66% (+0.01%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UOC
UBS O'Connor
Chicago,
Illinois
|
+$192K |
| 2 |
Dimensional Fund Advisors
Austin,
Texas
|
+$131K |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$122K |
| 4 |
Morgan Stanley
New York
|
+$24.3K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
+$13K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Two Sigma Advisers
New York
|
-$119K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$67.9K |
| 3 |
Millennium Management
New York
|
-$40K |
| 4 |
Osaic Holdings
Scottsdale,
Arizona
|
-$1.06K |
NVNO Hedge Fund Activity: Q3 2022 in Review
22 of the 5,828 institutional investors tracked by Wall St. Rank reported a position in enVVeno Medical (NVNO) for Q3 2022, worth a combined $13.7M — up 69% from $8.11M a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new NVNO positions and 2 closed out — a net gain of 1 holder — while 6 added to existing stakes and 2 trimmed.
The largest buyer was UBS O'Connor, adding an estimated $192K. The largest seller was Two Sigma Advisers, cutting an estimated $119K.
- 22 institutional investors held enVVeno Medical (NVNO) as of Q3 2022, up from 21 in Q2 2022.
- Funds reported $13.7M of enVVeno Medical stock for Q3 2022, up 69% quarter-over-quarter.
- 3 funds opened new enVVeno Medical positions in Q3 2022 and 2 closed out, a net change of +1 holder.
- The largest enVVeno Medical buyer in Q3 2022 was UBS O'Connor, an estimated $192K added.
- The largest enVVeno Medical seller in Q3 2022 was Two Sigma Advisers, an estimated $119K sold.
Based on aggregated 13F filings for Q3 2022.